Ardelyx is a biopharmaceutical company focused on developing medicines for people with cardiorenal diseases. This includes patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus; and CKD patients and/or heart failure patients with elevated serum potassium (hyperkalemia).Co.'s product pipeline includes the following: Tenapanor, an approach for the control of serum phosphorus in CKD patients on dialysis; DX013 Program, a small molecule for treating hyperkalemia; and IBSRELA® (tenapanor) a treatment for irritable bowel syndrome with constipation in adults. The ARDX stock yearly return is shown above.
The yearly return on the ARDX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARDX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|